Combined Metabolic Activators Therapy Ameliorates Liver Fat in Nonalcoholic Fatty Liver Disease Patients

Objective

To determine if combined metabolic activator supplementation (CMA) will reduce hepatic fat in nonalcoholic fatty liver disease (NAFLD) patients.

Study Design

Randomized, single-blind, placebo-controlled, phase II study in 31 patients with nonalcoholic fatty liver disease (NAFLD)

Dose

2000 mg

One dose of 3.73g L-carnitine tartrate, 1g NR, 12.35g serine, and 2.55g N-acetyl-L-cysteine for the first 14 days and two doses for the next 56 days.

Duration

10 weeks

Key Outcomes

  • CMA significantly decreased liver fat by 10%, and improved liver function, as seen through the significant reductions in serum ALT (39%), AST (30%), and uric acid (12%) levels.

  • CMA reduced plasma levels of inflammatory proteins, suggesting a decrease in liver inflammation.
    Fecal and salivatory sample analyses showed that CMA supplementation caused beneficial changes in the microbiome.

Clinical, Liver HealthANAD Staff